- Home
- / Kukje Pharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Kukje Pharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
₩5.5 K
2024-10-29
Market Capitalization
₩111.4 B
2024-10-29
Revenue
₩156.5 B
FY, 2024
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| KRW | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 107.7B | 111.1B | 130.4B | 119.7B | 126.6B | 135.4B | 156.5B |
| Cost of goods sold | 53.4B | 51.2B | 55.9B | 55.5B | 52.8B | 65.1B | 71.5B |
| Gross profit | 55.2B | 60.4B | 75.3B | 65.0B | 74.1B | 72.9B | 85.5B |
| Gross profit margin, % | 51.3% | 54.4% | 57.7% | 54.3% | 58.6% | 53.9% | 54.6% |
| Operating expense total | 48.3B | 51.1B | 64.8B | 61.5B | 64.0B | 68.1B | 75.1B |
| Depreciation and amortization | 3.9B | 3.3B | 3.6B | 4.4B | 5.0B | 6.1B | 3.2B |
| EBITDA | 6.9B | 9.3B | 10.4B | 3.5B | 10.1B | 4.8B | 10.4B |
| EBITDA margin, % | 6.4% | 8.3% | 8.0% | 2.9% | 8.0% | 3.6% | 6.7% |
| EBIT | 2.7B | 735.8M | 6.5B | (1.1B) | 5.1B | (6.1B) | 7.2B |
| EBIT margin, % | 2.5% | 0.7% | 5.0% | -0.9% | 4.0% | -4.5% | 4.6% |
| Interest income | 165.5M | 166.9M | 139.4M | 114.3M | 230.9M | 394.0M | 428.7M |
| Interest expense | 900.6M | 863.0M | 650.1M | 696.4M | 1.0B | 1.4B | 1.2B |
| Pre tax profit | 2.8B | 121.4M | 5.6B | (1.1B) | 4.7B | (6.7B) | 6.6B |
| Income tax expense | 647.4M | 4.9B | 3.4B | 445.5M | 1.2B | 1.7B | 1.4B |
| Net Income | 2.2B | (4.8B) | 2.2B | (1.6B) | 3.5B | (8.4B) | 5.2B |